GlassScriptPhysician profile
Laura Overton
NPI 1891339958
$1,978.23
in general payments reported to CMS, 2019-2025
27 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $109 · 2024: $637 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.24 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $290.94 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $165.57 | 2024-2025 | |
| Astellas Pharma US INC | $155.84 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $150.71 | 2023-2025 | |
| Exact Sciences Corporation | $125.62 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $125.36 | 2024-2025 | Korlym |
| Abbvie INC. | $124.75 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $119.15 | 2025 | |
| Lilly USA, LLC | $113.33 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Madrigal Pharmaceuticals | $94.22 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $87.31 | 2024-2025 | Shingrix, Trelegy Ellipta |
| Radius Health, INC. | $63.61 | 2024-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $53.98 | 2025 | Keveyis |
| Astrazeneca Pharmaceuticals LP | $49.97 | 2024-2025 | Airsupra, Flumist Quadrivalent |
| Calliditas Therapeutics US INC. | $31.33 | 2023 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.64 | 2025 | Inceptiv |
| Amgen INC. | $24.13 | 2024 | Tepezza |
| Pfizer INC. | $23.08 | 2025 | |
| Phathom Pharmaceuticals, INC. | $22.71 | 2024 | Voquezna |
| Abiomed | $19.66 | 2025 | |
| Dexcom, INC. | $19.39 | 2024 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $16.41 | 2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.98 | 2024 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.76 | 2024 | Lifevest |
| Kyowa Kirin, INC. | $14.07 | 2024 | Crysvita |
| Opko Pharmaceuticals, LLC | $13.97 | 2023 | Rayaldee |
| Mannkind Corporation | $13.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Overton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.